Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-TIP in Rare Advanced Tumors
NCT06684327Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel in extramammary Paget disease (EMPD), rhabdomyosarcoma (RMS), testicular cancer and 2 more, sponsored by Fudan University. Primary endpoint: Objective Response Rate at 12 weeks. Started Nov 2024; status: recruiting.
02
Drugs
nab-paclitaxel
03
Conditions
extramammary Paget disease (EMPD)rhabdomyosarcoma (RMS)testicular cancerpenile cancerurachal cancer
Beyond the preview
Go deeper on NCT06684327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684327.